Renzapride
Renzapride is a full serotonin 5-HT4 receptor agonist, partial serotonin 5-HT3 receptor antagonist.
Clinical Uses
Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme of the UK.